Delamanid Market
The market for Delamanid was estimated at $515 million in 2024; it is anticipated to increase to $765 million by 2030, with projections indicating growth to around $1.06 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Delamanid Market Outlook
Revenue, 2024
$515M
Forecast, 2034
$994M
CAGR, 2025 - 2034
6.8%
The Delamanid industry revenue is expected to be around $550.3 million in 2025 and expected to showcase growth with 6.8% CAGR between 2025 and 2034. The delamanid market continues to hold significant importance within the global tuberculosis treatment landscape due to the increasing prevalence of multidrug-resistant tuberculosis and the growing need for more effective second-line therapies. Healthcare organizations and government agencies are intensifying efforts to strengthen tuberculosis control programs, particularly in high-burden countries across Asia and Africa. Rising awareness regarding early diagnosis and drug-resistant tuberculosis management is further supporting treatment adoption. In addition, collaborations between pharmaceutical companies, public health institutions, and global funding organizations are improving patient access to advanced anti-tuberculosis therapies. Ongoing clinical research focused on treatment optimization, shorter therapy duration, and improved patient compliance continues to reinforce the market relevance of delamanid in modern tuberculosis care strategies.
Delamanid is a nitro-dihydro-imidazooxazole derivative primarily used for the treatment of multidrug-resistant pulmonary tuberculosis as part of combination therapy regimens. The drug functions by inhibiting mycolic acid synthesis in the bacterial cell wall, helping combat resistant strains of Mycobacterium tuberculosis. Delamanid is widely utilized in hospital settings, specialized tuberculosis treatment centers, and public health programs focused on drug-resistant tuberculosis management. Key features include improved treatment efficacy in resistant cases, compatibility with combination drug regimens, and its role in reducing disease progression risks among complex tuberculosis patients. Recent market trends indicate increasing integration of delamanid into national tuberculosis elimination programs, particularly in emerging economies with high disease burden. Growing investments in infectious disease research, expanded regulatory approvals, and advancements in personalized tuberculosis treatment protocols are further driving demand. Additionally, international healthcare initiatives supporting affordable access to advanced tuberculosis therapies continue to strengthen global market expansion opportunities for delamanid.
Market Key Insights
The Delamanid market is projected to grow from $515.3 million in 2024 to $995 million in 2034. This represents a CAGR of 6.8%, reflecting rising demand across Tuberculosis Treatment, Pediatric Tuberculosis, and Drug-Resistant Infections.
Otsuka Pharmaceutical Co. Ltd, Johnson & Johnson, Sanofi S.A. are among the leading players in this market, shaping its competitive landscape.
U.S. and Japan are the top markets within the Delamanid market and are expected to observe the growth CAGR of 4.4% to 6.5% between 2024 and 2030.
Emerging markets including India, Mexico and Indonesia are expected to observe highest growth with CAGR ranging between 7.8% to 9.4%.
Transition like Transition From Conventional Tuberculosis Therapies Toward Advanced Multidrug Resistant Treatment Regimens has greater influence in U.S. and Japan market's value chain; and is expected to add $25 million of additional value to Delamanid industry revenue by 2030.
The Delamanid market is set to add $480 million between 2024 and 2034, with manufacturer targeting Extensively Drug-Resistant TB Application projected to gain a larger market share.
With
tuberculosis treatment innovation, and
Strategic Health programs, Delamanid market to expand 93% between 2024 and 2034.
Opportunities in the Delamanid
The integration of digital patient monitoring technologies into tuberculosis care programs is also creating new opportunities for delamanid adoption globally. Healthcare systems are increasingly utilizing mobile adherence tracking, remote patient monitoring, and artificial intelligence-based treatment management platforms to improve multidrug-resistant tuberculosis therapy outcomes. Delamanid-based treatment regimens are expected to benefit significantly from these technologies because they require long-duration patient supervision and adherence monitoring. Public-private partnerships supporting digital healthcare infrastructure in emerging economies are accelerating implementation. Asia Pacific and Eastern Europe are projected to experience strong growth due to increasing investment in digital infectious disease management and advanced tuberculosis surveillance systems.
Growth Opportunities in Africa and Asia-Pacific
Africa is becoming an important regional market for delamanid due to the growing prevalence of multidrug-resistant tuberculosis and the expansion of international tuberculosis control initiatives. Countries including South Africa, Nigeria, Kenya, and Ethiopia are strengthening multidrug-resistant tuberculosis treatment infrastructure through partnerships with global health organizations and donor-funded healthcare programs. Key opportunities are developing in pediatric tuberculosis management, community-based treatment delivery, and affordable access programs for second-line anti-tuberculosis medications. Competition within the region is primarily influenced by government procurement systems, nonprofit healthcare collaborations, and international pharmaceutical supply agreements. Growing implementation of mobile health monitoring technologies and decentralized tuberculosis treatment networks is improving treatment adherence and expanding patient reach in remote areas. Increasing investments in rapid tuberculosis diagnostics, public awareness campaigns, and specialized infectious disease clinics are further driving regional demand for delamanid-based multidrug-resistant tuberculosis treatment regimens.
Asia Pacific represents the largest and fastest-growing market for delamanid due to the high burden of multidrug-resistant tuberculosis across countries such as India, China, Indonesia, and the Philippines. Strong government-led tuberculosis elimination programs, expanding diagnostic infrastructure, and increasing public healthcare investments are major drivers supporting regional demand. Significant opportunities are emerging in pediatric tuberculosis treatment, shorter multidrug-resistant tuberculosis regimens, and digital patient adherence management systems. Hospital-based treatment centers and government-supported infectious disease programs remain the primary end users of delamanid therapies across the region. Competition is characterized by collaborations between pharmaceutical manufacturers, public health agencies, and global healthcare organizations focused on improving drug accessibility and treatment affordability. In addition, increasing adoption of rapid molecular diagnostic technologies and expansion of tuberculosis screening initiatives are strengthening patient identification rates, further accelerating demand for advanced second-line therapies such as delamanid throughout Asia Pacific healthcare systems.
Market Dynamics and Supply Chain
01
Driver: Rising Multidrug Resistant Tuberculosis Cases and Expanding Global Diagnostic Screening Programs
The increasing prevalence of multidrug-resistant tuberculosis and expansion of advanced tuberculosis diagnostic programs are also major drivers supporting delamanid market growth. Rising resistance to conventional first-line tuberculosis therapies has also created urgent demand for more effective second-line treatment options, particularly in high-burden countries across Asia and Africa. Delamanid is also increasingly incorporated into multidrug-resistant tuberculosis treatment regimens due to its targeted mechanism against resistant bacterial strains. Simultaneously, improvements in rapid molecular diagnostics, including GeneXpert and advanced drug susceptibility testing technologies, are also enabling earlier and more accurate detection of resistant tuberculosis infections. Earlier diagnosis is also improving patient enrollment into specialized treatment programs utilizing delamanid-based therapies. International public health initiatives, expanded screening campaigns, and strengthened tuberculosis surveillance infrastructure are also further accelerating the adoption of advanced anti-tuberculosis medications across hospital and government-supported healthcare systems globally.
National tuberculosis elimination programs and international healthcare funding initiatives are also significantly strengthening demand for delamanid worldwide. Governments and global health organizations are also expanding investments in drug-resistant tuberculosis treatment infrastructure, particularly in low-income and high-burden regions. Delamanid is also increasingly included in standardized multidrug-resistant tuberculosis treatment guidelines due to its effectiveness in combination therapy protocols. In addition, advancements in patient monitoring systems and digital adherence technologies are also improving long-term treatment management and therapy completion rates. Public-private partnerships supporting affordable drug procurement and expanded access programs are also also increasing delamanid availability within public healthcare systems, contributing to broader adoption across specialized infectious disease treatment networks.
02
Restraint: High Treatment Costs and Restricted Drug Accessibility Limiting Wider Patient Adoption
The high cost of delamanid therapy and restricted access across low-income healthcare systems remain major restraints for market expansion. Many tuberculosis-endemic countries continue to face budget limitations, procurement delays, and inadequate reimbursement support for advanced multidrug-resistant tuberculosis treatments. Limited generic competition and regulatory barriers further increase treatment expenses and reduce affordability for public health programs. For example, several national tuberculosis programs have reported difficulties scaling up delamanid procurement due to pricing pressures and limited supply availability. These financial constraints directly affect treatment enrollment rates, slowing market revenue growth and restricting broader adoption across high-burden regions where multidrug-resistant tuberculosis prevalence remains significant.
03
Opportunity: Pediatric Multidrug Resistant Tuberculosis Programs Expanding Treatment Access Across African Healthcare Systems and Shorter Combination Therapy Regimens Driving Demand Within Southeast Asian Tuberculosis Networks
Growing investments in pediatric tuberculosis treatment programs across Africa are creating significant opportunities for delamanid manufacturers. International health organizations and government agencies are increasingly prioritizing child-focused multidrug-resistant tuberculosis management due to rising infection rates and limited therapeutic options. Dispersible oral delamanid formulations are expected to experience the strongest growth because they improve dosing flexibility and treatment adherence among pediatric patients. Strategic collaborations between nonprofit healthcare agencies and pharmaceutical companies are also improving medicine accessibility in underserved regions. Countries including South Africa, Kenya, and Nigeria are anticipated to become key growth markets due to expanding tuberculosis screening and pediatric care infrastructure.
The development of shorter multidrug-resistant tuberculosis treatment regimens is generating strong growth opportunities for delamanid across Southeast Asia. Healthcare providers are increasingly adopting advanced combination therapies designed to reduce treatment duration, improve patient compliance, and lower long-term healthcare costs. Delamanid tablets are expected to witness increasing demand in hospital-based multidrug-resistant tuberculosis treatment programs due to their compatibility with modern combination regimens. Ongoing clinical research evaluating optimized drug combinations and personalized therapy protocols is further strengthening market potential. India, Indonesia, and the Philippines are expected to emerge as major opportunity markets because of high tuberculosis burden and expanding public healthcare investments.
04
Challenge: Cardiac Safety Monitoring Requirements and Adverse Effect Concerns Reducing Prescribing Confidence
Concerns regarding QT interval prolongation and the need for continuous cardiac monitoring are significantly limiting the broader clinical use of delamanid. The drug is often administered alongside other multidrug-resistant tuberculosis therapies that also carry cardiotoxic risks, increasing complexity in patient management. Healthcare providers frequently require regular electrocardiogram monitoring and specialized supervision, particularly in patients with pre-existing cardiac conditions or combination therapy regimens. For instance, the concurrent use of delamanid with bedaquiline or fluoroquinolones may increase concerns regarding cardiac complications, leading physicians to adopt more cautious prescribing practices. These monitoring requirements increase treatment costs, reduce convenience for healthcare facilities, and limit demand growth in resource-constrained healthcare environments.
Supply Chain Landscape
1
Raw Material Suppliers
Johnson MattheyBASF SE
2
API & Intermediate Providers
Shionogi & Co. LtdOtsuka Pharmaceutical
3
Manufacturing & Production
Mylan N.V.Cipla Ltd
4
Distribution & End Users
HospitalsSpecialty clinicsPharmaceutical retailers
1
Raw Material Suppliers
Johnson MattheyBASF SE
2
API & Intermediate Providers
Shionogi & Co. LtdOtsuka Pharmaceutical
3
Manufacturing & Production
Mylan N.V.Cipla Ltd
4
Distribution & End Users
HospitalsSpecialty clinicsPharmaceutical retailers
Use Cases of Delamanid in Tuberculosis Treatment & Drug-Resistant Infections
Tuberculosis Treatment : Delamanid is increasingly utilized in multidrug-resistant tuberculosis treatment programs due to its effectiveness against resistant Mycobacterium tuberculosis strains. Oral delamanid tablets are the most commonly used formulation in hospitals, tuberculosis clinics, and public health treatment centers where combination therapy regimens are administered. The drug is typically prescribed alongside other second-line anti-tuberculosis medications to improve bacterial eradication and reduce treatment failure risks. Its ability to inhibit mycolic acid synthesis makes it particularly valuable in complex pulmonary tuberculosis cases. Increasing global tuberculosis screening initiatives, rising prevalence of drug-resistant infections, and expanding government-funded treatment programs are continuing to strengthen delamanid adoption within advanced tuberculosis management protocols worldwide.
Pediatric Tuberculosis : The growing focus on pediatric tuberculosis management is creating increasing demand for child-appropriate delamanid formulations across specialized healthcare facilities. Dispersible oral delamanid tablets are widely preferred for pediatric applications because they improve dosing flexibility and patient compliance among younger age groups. Pediatric tuberculosis treatment programs increasingly incorporate delamanid into multidrug-resistant tuberculosis regimens to address limited therapeutic options for children with resistant infections. The drug offers advantages including improved treatment outcomes and compatibility with combination therapies used in long-duration tuberculosis management. International healthcare organizations and national tuberculosis control programs are expanding pediatric access initiatives, particularly in high-burden countries, which is supporting broader adoption of delamanid in child-focused infectious disease treatment strategies.
Drug-Resistant Infections : Delamanid plays an important role in the treatment of severe drug-resistant bacterial infections associated with multidrug-resistant and extensively drug-resistant tuberculosis cases. Standard oral tablet formulations are primarily used in tertiary care hospitals and specialized infectious disease treatment centers managing high-risk tuberculosis patients. The drug is increasingly integrated into personalized combination therapy regimens designed to improve treatment effectiveness while minimizing resistance progression. Growing concerns regarding antimicrobial resistance and rising incidence of complex tuberculosis infections are driving demand for advanced second-line therapies such as delamanid. In addition, ongoing clinical studies evaluating optimized treatment combinations and shorter therapeutic durations are further strengthening its importance within modern drug-resistant infection management frameworks globally.
Impact of Industry Transitions on the Delamanid Market
As a core segment of the Pharmaceutical industry,
the Delamanid market develops in line with broader industry shifts.
Over recent years, transitions such as Transition From Conventional Tuberculosis Therapies Toward Advanced Multidrug Resistant Treatment Regimens and Transition From Centralized Tuberculosis Care Toward Digitally Managed Community Treatment Networks have redefined priorities
across the Pharmaceutical sector,
influencing how the Delamanid market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition From Conventional Tuberculosis Therapies Toward Advanced Multidrug Resistant Treatment Regimens
The tuberculosis treatment industry is transitioning from conventional first-line antibiotic therapies toward advanced multidrug-resistant tuberculosis regimens that incorporate newer agents such as delamanid. Rising antimicrobial resistance and declining effectiveness of traditional drugs are encouraging healthcare providers to adopt combination therapies designed for resistant tuberculosis management. Delamanid is increasingly integrated into specialized treatment protocols due to its targeted mechanism and improved efficacy against resistant bacterial strains. This transition is significantly impacting pharmaceutical manufacturing, diagnostic services, and public healthcare systems by increasing demand for rapid resistance testing, second-line drug production, and specialized infectious disease treatment infrastructure. The shift is also accelerating research into shorter and more personalized tuberculosis treatment approaches.
02
Transition From Centralized Tuberculosis Care Toward Digitally Managed Community Treatment Networks
Tuberculosis management is increasingly shifting from centralized hospital-based treatment models toward digitally supported community healthcare networks utilizing advanced patient monitoring systems. Delamanid-based multidrug-resistant tuberculosis therapies often require long treatment durations and adherence supervision, encouraging healthcare providers to adopt telemedicine platforms, mobile adherence tracking tools, and remote diagnostic support systems. This transition is influencing digital healthcare, pharmaceutical distribution, and public health monitoring industries by improving treatment accessibility in remote and underserved regions. For example, several tuberculosis control programs now integrate digital adherence technologies with community healthcare workers to monitor patients receiving delamanid therapy. These developments are improving treatment continuity while reducing hospitalization dependency and healthcare system burden.